Author:
Hastings Richard,Ding Tina,Butt Sayqa,Gadsby Kate,Zhang Weiya,Moots Robert J.,Deighton Chris
Reference25 articles.
1. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis;Tetta;Ann Rheum Dis,1990
2. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept;Fleischmann;Drug Saf,2002
3. Adalimumab, a fully human anti tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis);Furst;J Rheumatol,2003
4. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-α antagonists in patients with rheumatoid arthritis?;Ang;J Rheumatol,2003
5. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001);Ledingham;Rheumatology (Oxford),2005
Cited by
85 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献